P. Wersåll

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

I. Bodrogi, P. Conte, L. Dogliotti, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus statement Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma

H. Onishi, S. Lo, A. Muacevic, 2016 .

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

I. Bodrogi, P. Conte, H. von der Maase, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Different dose regimens of the mouse monoclonal-antibody 17-1a for therapy of patients with metastatic colorectal-carcinoma.

J. Fagerberg, K. Fox, K. Thor, 1995, International journal of oncology.

Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma.

H. Onishi, S. Lo, A. Muacevic, 2016, Future oncology.

Unique proteomic signature for radiation sensitive patients; a comparative study between normo-sensitive and radiation sensitive breast cancer patients.

S. Tapio, M. Harms-Ringdahl, S. Haghdoost, 2015, Mutation research.

Cancer chemotherapy and biological response modifyers, annual 14

P. Wersåll, 1995 .